Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting ...

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic ...

Francis added that when he came to Teva he sensed the market’s skepticism about the company’s ability to return to innovative ...

Teva Pharmaceutical Industries (NYSE:TEVA) recently made headlines by upsizing its senior notes offering to approximately ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...